期刊论文详细信息
BMC Biotechnology
Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureus Panton-Valentine leukocidin for Diagnostic and Therapeutic Applications
Charles Emeka Okolie1  Alan Cockayne2  Christopher Penfold2  Richard James2 
[1] Department of Biological Sciences, College of Science and Engineering, Landmark University, Omu-Aran, Kwara State, Nigeria
[2] School of Molecular Medical Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2UH, UK
关键词: Immuno-therapy;    Mass spectrometry;    Chromatography;    Leukocytolytic exotoxin;    Panton-Valentine leukocidin;    Staphylococcus aureus;   
Others  :  835078
DOI  :  10.1186/1472-6750-13-103
 received in 2013-09-09, accepted in 2013-10-31,  发布年份 2013
PDF
【 摘 要 】

Background

Staphylococcus aureus produces several toxins, including Panton-Valentine leukocidin (PVL). The involvement of PVL in primary skin infections, necrotizing pneumonia, musculoskeletal disorders, brain abscess, and other diseases, some of which are life-threatening, has been reported. Following expert opinion, we aimed to provide the tools for establishment of sequence-based diagnostics and therapeutics for those conditions. We engineered the synergistic S and F (LukS-PV and LukF-PV respectively) pro-toxin subunits from Staphylococcus aureus USA400 into separate expression E. coli BL21(DE3)-pLysS hosts.

Results

Following Nickel affinity chromatography (NAC), the F subunit came out without bands of impurity. The S sub-unit did not come off very pure after NAC thus necessitating further purification by size exclusion and ion-exchange chromatography. The purification plots showed that the BioLogic-LP and AKTA systems are reliable for following the progress of the chromatographic purification in real-time. Computer predicted Mw for the 6His-LukF-PV and 6His-LukS-PV were 35645.41 Da and 33530.04 Da respectively, while the mass spectrometry results were 35643.57 Da and 33528.34 Da respectively.

Conclusion

The BioLogic-LP and AKTA systems are commendable for reliability and user-friendliness. As a recent work elsewhere also reported that a second round of chromatography was necessary to purify the S subunit after the first attempt, we speculate that the S subunit might contain yet unidentified motif(s) requiring further treatment. The purified S and F sub-units of PVL were supplied to the Nottingham Cancer Immunotherapy group who used them to establish sequence-based monoclonal antibodies for diagnostic and therapeutic uses targeting PVL.

【 授权许可】

   
2013 Okolie et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140715100547509.pdf 1579KB PDF download
Figure 7. 54KB Image download
Figure 6. 44KB Image download
Figure 5. 53KB Image download
Figure 4. 112KB Image download
Figure 3. 49KB Image download
Figure 2. 49KB Image download
Figure 1. 20KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Supersac G, Prevost G, Piemont Y: Sequencing of leucocidin R from Staphylococcus aureus P83 suggests that staphylococcal leucocidins and gamma-hemolysin are members of a single, two-component family of toxins. Infect Immun 1993, 61:580-587.
  • [2]Prevost G, Bouakham T, Piemont Y, Monteil H: Characterisation of a synergohymenotropic toxin produced by Staphylococcus intermedius. FEBS Bp 1995a, 376:135-140.
  • [3]Kaneko J, Kamio Y: Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004, 68:981-1003.
  • [4]Prevost G, Cribier B, Couppie P, Petiau P, Supersac G, Finck-Barbancon V, et al.: Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun 1995b, 63:4121-4129.
  • [5]Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al.: Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006, 367(9512):731-739.
  • [6]Ma XX, Ito T, Kondo Y, Cho M, Yoshizawa Y, Kaneko J, Katai A, Higashiide M, Li S, Hiramatsu K: Two different Panton-Valentine leukocidin phage lineages predominate in Japan. J Clin Microbiol 2008, 46(10):3246-3258.
  • [7]Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K-I, Oguchi A, et al.: Genome and virulence determinants of high virulence community-acquired MRSA. The Lancet 2002, 359:1819-1827.
  • [8]Hiramatsu K, Watanabe S, Takeuchi F, Ito T, Baba T: Genetic characterization of methicillin-resistant Staphylococcus aureus. Vaccine 2004, 22(1):S5-S8.
  • [9]Panton PN, Valentine FCO: Staphylococcal toxin. The Lancet 1932, 219:506-508.
  • [10]Hay RJ, Steer AC, Engelman D, Walton S: Scabies in the developing world–its prevalence, complications, and management. Clin Microbiol Infect 2012, 18(4):313-323.
  • [11]Prevost G, Couppie P, Prevost P, Gayet S, Petiau P, Cribier B, et al.: Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995, 42:237-245.
  • [12]Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter M-O, Gauduchon V, et al.: Involvement of Panton-Valentine alentine leukocidin-producing staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128.
  • [13]Schleucher RD, Gaessler M, Knobloch J: Panton-Valentine leukocidin-producing methicillin-sensitive staphylococcus aureus as a cause for recurrent, contagious skin infections in young, healthy travelers returned from a tropical country: a new worldwide public health problem? J Travel Med 2008, 15:137-139.
  • [14]Muttaiyah S, Coombs G, Pandey S, Reed P, Ritchie S, Lennon D, et al.: Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. J Clin Microbiol 2010, 48(10):3470-3474.
  • [15]Jung N, Lehmann C, Hellmann M, Seifert H, Valter MM, Hallek M, et al.: Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin's abscess. Infect Dis Obstet Gynecol 2008, 2008:491401. doi: 10.1155/2008/491401
  • [16]Schefold JC, Esposito F, Storm C, Heuck D, Krüger A, Jörres A, et al.: Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report. J. Med. Case Reports 2007, 1:165.
  • [17]Skov R: Panton-Valentine-leukocidin producing Staphylococcus aureus as the cause of necrotizing pneumonia and death. Ugeskr Laeger 2010, 172(16):1189.
  • [18]Rabol PH, Dessau RB, Bjerglund L: Fatal pneumonia with Panton-Valentine leucocidin-producing Staphylococcus aureus. Ugeskr Laeger 2010, 172(16):1190-1191.
  • [19]Dubrous P, Cuguillère A, Gendrot A, Koeck JL: Panton-Valentine leukocidin-producing Staphylococcus aureus responsible for necrotizing pneumonia. Ann Biol Clin (Paris) 2007, 65(3):277-281.
  • [20]Akpaka PE, Monecke S, Swanston WH, Rao AC, Schulz R, Levett PN: Methicillin sensitive Staphylococcus aureus producing Panton-Valentine leukocidin toxin in Trinidad & Tobago: a case report. J Med Case Rep 2011, 5:157.
  • [21]Al-Talib H, Hasan H, Yean CY, Al-Ashwal SM, Ravichandran M: Fatal necrotizing pneumonia caused by Panton-Valentine leukocidin-producing hospital-acquired Staphylococcus aureus: a case report. Jpn J Infect Dis 2011, 64(1):58-60.
  • [22]Catena V, Baiocchi M, Lentini P, Badolati L, Baccarin M, Del Monte DD, Rubini A: Necrotizing pneumonia caused by Panton-Valentine leukocidin-producing methicillin-susceptible Staphylococcus aureus (MSSA). Infez Med 2010, 20(3):205-210.
  • [23]Rafai M, Abouelalaa K, Skhsoukh Y, Balkhi H, Belyamani L, Dimou M: Evolution of a fatal septic arthritis caused by a Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus strain. Joint Bone Spine 2013, 80(5):525-527.
  • [24]Ramos A, Ley L, Muñez E, Videl A, Sánchez I: Brain abscess due to Panton-Valentine leukocidin-positive Staphylococcus aureus. Infection 2009, 37(4):365-367.
  • [25]Enany S, Higuchi W, Okubo T, Takano T, Enany M, Yamamoto T: Brain abscess caused by Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus in Egypt, April 2007. Euro Surveill 2007., 12(39)
  • [26]Noah MA, Dawrant M, Faulkner GM, Hill AM, Harvey C, Hussain A, Jenkins DR, Nichani S, Peek GJ, Sosnowski AW, Firmin RK: Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: experience and outcome. Crit Care Med 2010, 38(11):2250-2253.
  • [27]Enany S, Yaoita E, Yoshida Y, Enany M, Yamamoto T: Molecular characterization of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolates in Egypt. Microbiol Res 2010, 165(2):152-162.
  • [28]Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, Vandenesch F, Etienne J, Lina G: Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 2011, 38(6):457-464.
  • [29]Morgan MS: Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia. Int J Antimicrob Agents 2007, 30(4):289-296.
  • [30]Morgan M: Staphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia. BMJ 2005, 331:793-794.
  • [31]Hooker RS: The treatment of staphylococcus septicaemia by transfusion of immune blood. Ann Surg 1917, 66:513-521.
  • [32]Gauduchon V, Cozon G, Vandenesch F, Genestier A-L, Eyssade N, Peyrol S, et al.: Neutralization of staphylococcus aureus Panton valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189:346-353.
  • [33]Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: a Laboratory Manual. 2nd edition. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989.
  • [34]Bardelang P, Vankemmelbeke M, Zhang Y, Jarvis H, Antoniadou E, Rochette S, Thomas NR, Penfold CN, James R: Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lysostaphin. Biochem J 2009, 418(3):615-624.
  • [35]Centers for Disease Control and Prevention and National Institutes of Health: Biosafety in Microbiological and Biomedical Laboratories. 5th edition. Washington: United States Government Printing Office; 2007.
  • [36]Chen CC, Hwang JK, Yang JM: (PS)2: Protein structure prediction server. Nuc Acids Res 2006, 34(suppl 2):W152-W157. Available at: http://ps2.life.nctu.edu.tw/ webcite
  • [37]Warfield R, Bardelang P, Saunders H, Chan WC, Penfold C, James R, Thomas NR: Internally quenched peptides for the study of lysostaphin: an antimicrobial protease that kills Staphylococcus aureus. Org Biomol Chem 2006, 4:3626-3638.
  • [38]Chang V, Ling-Yi C, Wang A, Yuan X: The effect of Lipopolysaccharide core structure defects on transformation efficiency in isogenic Escherichia coli BW25113 rfaG, rfaP, and rfaC mutants. J ExpMicrobiol Immunol (JEMI) 2010, 14:101-107.
  • [39]Kuo WH, Chase HA: Exploiting the interactions between poly-histidine fusion tags and immobilized metal ions. Biotechnol Lett 2011, 33(6):1075-1084.
  • [40]Kanade RP, Notani NK: Cloning and characterization of a DNA repair gene in Haemophilus influenzae. J Biosci 1987, 12(2):115-123.
  • [41]Liu YG, Nagaki K, Fujita M, Kawaura K, Uozumi M, Ogihara Y: Development of an efficient maintenance and screening system for large-insert genomic DNA libraries of hexaploid wheat in a transformation-competent artificial chromosome (TAC) vector. Plant J 2000, 23(5):687-695.
  • [42]Graves SF, Kobayashi SD, Braughton KR, Diep BA, Chambers HF, Otto M, et al.: Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants. Microbes Infect 2010, 12(6):446-456.
  • [43]Sriwanthana B, Island MD, Maneval D, Mobley HL: Single-step purification of Proteus mirabilis urease accessory protein UreE, a protein with a naturally occurring histidine tail, by nickel chelate affinity chromatography. J Bacteriol 1994, 176(22):6836-6841.
  文献评价指标  
  下载次数:27次 浏览次数:25次